{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-017768","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.537557+00:00","generated_at":"2026-06-02T23:25:17.698515+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Abeona Therapeutics prices $75M underwritten offering of common stock and pre-funded warrants","bullets":["Offering: 12,285,056 common shares at $4.07/share and 6,142,656 pre-funded warrants at $4.0699 each.","Gross proceeds ~$75M; net proceeds ~$70.2M after underwriting discounts and expenses.","Closing expected May 7, 2024; Stifel is sole bookrunner.","Proceeds to fund BLA resubmission and commercialization of pz-cel, plus working capital.","New and existing investors participating include Adage Capital, Janus Henderson, Nantahala, Suvretta, Vivo Capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-017768","json":"https://secwatch.observer/filing/0001493152-24-017768.json","markdown":"https://secwatch.observer/filing/0001493152-24-017768.md","text":"https://secwatch.observer/filing/0001493152-24-017768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315224017768/0001493152-24-017768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315224017768/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:25:17.698515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f6c5a0748ec25c2ffaeeb257bb674318926192d9","claim":"ABEONA THERAPEUTICS INC. entered into Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated valued at $70.2 million (effective 2024-05-03).","evidence_excerpt":"On May 3, 2024, Abeona Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Underwriter”) relating to the issuance and sale of an aggregate of (a) 12,285,056 shares of the Company’s common stock (the “Shares”), and (b) pre-funded warrants to purchase 6,142,656 shares of the Company’s common stock (the “Pre-Funded Warrants”) in an underwritten offering (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224017768/0001493152-24-017768-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Stifel, Nicolaus & Company, Incorporated"},{"label":"Value","value":"$70.2 million"},{"label":"Effective","value":"2024-05-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}